- Prescient Therapeutics received new US Patent from the USPTO for companion diagnostic for PTX-100.
- It is another significant move for PTX in building a deep product pipeline of personalised targeted therapies and tools for treating cancer patients.
- After receiving grant from the USPTO, the patent is projected to be valid until 2031.
Prescient Therapeutics Limited (ASX:PTX) has received a notice of allowance from the USPTO (the United States Patent and Trademark Office) for a new patent for its anti-cancer compound PTX-100.
PTX-100 is a first in class compound that blocks an important cancer growth enzyme. It is currently being examined in a PK/PD basket study of hematological and solid malignancies. The study is focused on cancers predisposed to Ras and RhoA mutations.
Let us discuss in detail-
Prescient Therapeutics added one more feather to its IP Portfolio
On 26 October 2020, Prescient updated that the Company had received a notice of allowance from USPTO for a new patent for its anti-cancer compound PTX-100.
The patent covers methods for using a specific biomarker to stratify patients of breast tumor and identify patients who are most likely to respond to treatment with PTX-100.
The patent (13/194,022) is entitled as “Methods for inducing tumor regression and inhibiting tumor growth, and inducing apoptosis in breast tumors with geranylgeranyl transferase -1 inhibitors”
Post the grant from the US patent office, the patent is anticipated to be valid until 2031.
It is noteworthy to mention that this is another important addition to Prescient's strong IP portfolio. The patent enhances protection of PTX-100 as well as its potential use for breast cancer treatment.
Previously, the Company in-licensed the p27 biomarker from the H. Lee Moffitt Cancer Center. This license enables it to use p27 biomarker as a companion diagnostic with PTX-100, on a basis that patients having low p27 levels would be more likely to respond positively to PTX-100 treatment.
CEO and Managing Director of Prescient Therapeutics, Steven Yatomi-Clarke stated-
PTX-100 in Brief
PTX-100 works by disrupting oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells. The disruption then leads to apoptosis (death) of cancer cells.
PTX-100 is the only RhoA inhibitor under clinical development across the world, as per Prescient Therapeutics.
Currently, the compound is being investigated in a PK/PD basket study of hematological and solid malignancies, focusing on cancers predisposed to Ras and RhoA mutations.
In a previous Phase 1 clinical trial for advanced solid tumors demonstrated PTX-100 was well-tolerated and helped in achieving a disease stabilisation in patients.
With this significant achievement, Prescient Therapeutics further boosts protection of PTX-100 and its potential use for breast cancer treatment. Additionally, the patent grant will strengthen the strong intellectual property portfolio of the Company.
On 26 October 2020, the PTX share price was quoted at A$0.058 (at AEDT 1:47 PM) with a market capitalisation of A$38.43 million.
To know more about Prescient Therapeutics Limited, click here.
To stay updated with PTX company activities and announcements, please update your details on their investor centre.